Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Русский
English
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ADAG
#3090
Adagene Inc. American Depositary Shares
2.9
6
-7.21%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-7.21%
Aylık değişim
+24.37%
6 aylık değişim
+37.67%
Yıllık değişim
+42.31%
Önceki kapanış
3.1
9
Open
2.9
6
Bid
Ask
Low
2.9
6
High
2.9
6
Hacim
1
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
ADAG
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
58.89 M
222.69 M
Valuation ratios
Enterprise value
37.28 M
275.25 M
Price to earnings ratio
-3.37
-15.36
Price to sales ratio
—
—
Price to cash flow ratio
-3.77
-18.25
Price to book ratio
2.22
7.14
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
-0.01
0.07
Return on equity %
-0.01
0.11
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
2.3
14.85
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
0.06
0.41
Debt to equity ratio
0.1
0.7
Long term debt to total assets ratio
0
0.23
Long term debt to total equity ratio
0.01
0.39
Per share metrics
Operating cash flow per share
-0.01
0.27
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
0.09
1
Cash per share
1.51
9.66
Net current asset value per share
1.56
10.11
Tangible book value per share
0.9
6.85
Working capital per share
0.88
7.24
Book value per share
0.9
6.85
Haberler
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
Акции Adagene взлетели после ускоренного одобрения FDA
Adagene stock soars after FDA grants Fast Track status for cancer therapy
FDA предоставляет музастотугу от Adagene статус ускоренной разработки
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer
Adagene начинает испытания музастотуга для лечения MSS CRC
Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Акции Adani растут после отклонения SEBI обвинений Hindenburg
Adani shares rally as SEBI dismisses Hindenburg allegations